Patient-derived conditionally reprogrammed cells maintain intra-tumor genetic heterogeneity.

ABSTRACT: Preclinical in vitro models provide an essential tool to study cancer cell biology as well as aid in translational research, including drug target identification and drug discovery efforts. For any model to be clinically relevant, it needs to recapitulate the biology and cell heterogeneity of the primary tumor. We recently developed and described a conditional reprogramming (CR) cell technology that addresses many of these needs and avoids the deficiencies of most current cancer cell lines, which are usually clonal in origin. Here, we used the CR cell method to generate a collection of patient-derived cell cultures from non-small cell lung cancers (NSCLC). Whole exome sequencing and copy number variations are used for the first time to address the capability of CR cells to keep their tumor

SUBMITTER: Correa BRS 

PROVIDER: S-EPMC5840339 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature